Matthew Killeen - Dec 1, 2022 Form 4 Insider Report for Renovacor, Inc. (RCOR)

Role: Chief Scientific Officer
Signature: /s/ Joseph Carroll, as attorney-in-fact
Stock symbol: RCOR
Transactions as of: Dec 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 12/5/2022, 08:21 PM
Previous filing: Jan 26, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCOR	Common Stock	Disposed to Issuer		-5.28K	-100%		0	Dec 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCOR	Stock Option	Disposed to Issuer	$0	-194K	-100%	$0.00^*	0	Dec 1, 2022	Common Stock	194K		Direct	F2, F3
transaction	RCOR	Stock Option	Disposed to Issuer	$0	-10.6K	-100%	$0.00^*	0	Dec 1, 2022	Common Stock	10.6K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Matthew Killeen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock underlying Company Time-Vesting RSUs (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")). Each unvested RSU outstanding immediately prior to the First Effective Time (as defined in the Merger Agreement) was accelerated, cancelled and converted into the right to receive a number of Rocket common stock, rounded to the nearest whole number, equal to the number of shares of Issuer common stock underlying such Company Time-Vesting RSU multiplied by the Exchange Ratio (as defined in the Merger Agreement).
F2	Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
F3	Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.